CD22

Across TCGA pan-cancer cohorts, CD22 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of CD22’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where CD22 RNA is repressed in tumor relative to normal tissue. In most cancer types CD22 is over-expressed in tumor, although a few such as BLCA and COAD show the opposite, repressed pattern.

BLCA, COAD, and KIRC are the cancer types where CD22 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CD22 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	III,IV	−1.422	.001	10	view →
COAD	Female	II,III,IV	−1.518	<.001	8	view →
KIRC	All	All	+0.628	<.001	8	view →
UCEC	All	II,III,IV	−3.452	<.001	6	view →
LUSC	Female	All	−1.873	<.001	6	view →
BRCA	All	All	+0.619	<.001	6	view →
LUAD	All	All	−0.590	.001	6	view →
KIRP	All	All	+0.976	<.001	5	view →
KICH	All	All	+1.762	<.001	4	view →
CHOL	All	All	+0.904	.020	2	view →
HNSC	Female	III,IV	+0.484	.005	2	view →
THCA	Male	All	+1.222	.023	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

CD22–BLCA

Open the BLCA breakdown →